Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
Subscribe To Our Newsletter & Stay Updated
